1. Home
  2. AAM vs ALT Comparison

AAM vs ALT Comparison

Compare AAM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AAM
  • ALT
  • Stock Information
  • Founded
  • AAM 2024
  • ALT 1997
  • Country
  • AAM United States
  • ALT United States
  • Employees
  • AAM N/A
  • ALT N/A
  • Industry
  • AAM
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • AAM
  • ALT Health Care
  • Exchange
  • AAM Nasdaq
  • ALT Nasdaq
  • Market Cap
  • AAM 467.9M
  • ALT 501.9M
  • IPO Year
  • AAM 2024
  • ALT N/A
  • Fundamental
  • Price
  • AAM $10.60
  • ALT $5.13
  • Analyst Decision
  • AAM
  • ALT Strong Buy
  • Analyst Count
  • AAM 0
  • ALT 7
  • Target Price
  • AAM N/A
  • ALT $16.33
  • AVG Volume (30 Days)
  • AAM 40.8K
  • ALT 3.2M
  • Earning Date
  • AAM 01-01-0001
  • ALT 11-06-2025
  • Dividend Yield
  • AAM N/A
  • ALT N/A
  • EPS Growth
  • AAM N/A
  • ALT N/A
  • EPS
  • AAM 0.33
  • ALT N/A
  • Revenue
  • AAM N/A
  • ALT $20,000.00
  • Revenue This Year
  • AAM N/A
  • ALT N/A
  • Revenue Next Year
  • AAM N/A
  • ALT N/A
  • P/E Ratio
  • AAM $32.04
  • ALT N/A
  • Revenue Growth
  • AAM N/A
  • ALT N/A
  • 52 Week Low
  • AAM $10.04
  • ALT $2.90
  • 52 Week High
  • AAM $10.79
  • ALT $10.88
  • Technical
  • Relative Strength Index (RSI)
  • AAM 52.30
  • ALT 73.15
  • Support Level
  • AAM $10.56
  • ALT $4.40
  • Resistance Level
  • AAM $10.64
  • ALT $4.75
  • Average True Range (ATR)
  • AAM 0.04
  • ALT 0.30
  • MACD
  • AAM -0.01
  • ALT 0.09
  • Stochastic Oscillator
  • AAM 28.57
  • ALT 94.86

About AAM AA Mission Acquisition Corp. Class A Ordinary Shares

AA Mission Acquisition Corp is a blank check company.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: